Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pulmatrix's iSPERSE inhaled drug platform showed multi-drug delivery abilities and superiority over conventional lactose blending for an effective therapeutic dose of the active ingredients in Advair, salmeterol and fluticasone, as well as an additional anticholinergic bronchodilator.
Subscribe to our email newsletter
iSPERSE is a novel inhaled dry powder delivery platform developed by Pulmatrix for use in the delivery of drugs via inhalation for local or systemic applications.
The preclinical data of iSPERSE suggested that it can efficiently deliver consistent double- and triple-combination drug doses and offers improved drug efficacy and safety for patients having both normal and lower or impaired lung function.
In the in vitro and preclinical studies, an iSPERSE fluticasone and salmeterol combination was matched to commercially available Advair Diskus, which contains the fluticasone and salmeterol combination blended with lactose to enable pulmonary delivery.
iSPERSE demonstrated improved delivery efficiency over Advair Diskus, as iSPERSE was shown to deliver over 2 times more lung dose of the active pharmaceutical ingredients than Advair Diskus.
In addition, iSPERSE behaved flow rate independently at flow rates of 28.3 and 60.0 LPM, maintaining a similar fine particle fraction when tested via actuation from a capsule-based passive dry powder inhaler.